Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders Riccardo Dalle Grave, MD Department of Eating and Weight Disorders, Villa Garda Hospital, Garda (VR), Italy Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications for managing obesity and related metabolic complications

placebo in the fall of eGFR was better among patients with macroalbuminuria or in those with eGFR between 3060 ml/min/1.73 m2,100 and in the AWARD-7 trial the effect of dulaglutide on renal clinical outcomes and eGFR decline was more pronounced in participants with macroalbuminuria at baseline.66 Likewise, in a post hoc analysis of the LEADER study those patients who experienced a 30% reduction in albuminuria during follow-up had fewer cardiovascular and renal events,101 which confirms that a reduction in albuminuria is associated with a reduction in cardiovascular and renal events.99,102 Finally, the renal benefits of arGLP-1 appear to be additive to those of iSGLT2, which is of particular interest in patients with DKD.85,86,103 Cardiovascular and renal benefits of these drugs have been also demonstrated in real-life studies.104105 The causes of renal protection by some arGLP-1 s are unclear

The mean age was 59.25 years (range, 30-80 years).The indications for treatment were actinic keratosis (7 patients, 35%), basal cell carcinoma (6 patients, 30%), actinic keratosis and basal cell carcinoma (3 patients, 15%), necrobiosis lipoidica (1 patient, 5%), porokeratosis (1 patient, 5%), and segmental Darier disease (1 patient, 5%)
Here are some tips on how to monitor and report side effects effectively: Keep a Symptom Diary: Write down any skin changes you notice, including when they occur, how long they last, and any factors that might have triggered them
GLP-1 usage went astronomically high, [and] all the projections that you hear from the research companies are that it will continue, said The Vitamin Shoppe president Muriel Gonzalez